NASDAQ:SHPG - Shire Stock Price, Price Target & More

$163.62 +2.88 (+1.79 %)
(As of 04/20/2018 02:06 PM ET)
Previous Close$160.74
Today's Range$159.81 - $164.99
52-Week Range$123.73 - $192.15
Volume3.03 million shs
Average Volume1.47 million shs
Market Capitalization$49.40 billion
P/E Ratio10.80
Dividend Yield0.64%
Beta1.31

About Shire (NASDAQ:SHPG)

Shire logoShire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Receive SHPG News and Ratings via Email

Sign-up to receive the latest news and ratings for SHPG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SHPG
CUSIPN/A
Phone353-1609-6000

Debt

Debt-to-Equity Ratio0.46%
Current Ratio0.97%
Quick Ratio0.55%

Price-To-Earnings

Trailing P/E Ratio10.80
Forward P/E Ratio10.75
P/E Growth1.28

Sales & Book Value

Annual Sales$15.16 billion
Price / Sales3.28
Cash Flow$22.8839 per share
Price / Cash7.15
Book Value$119.43 per share
Price / Book1.37

Profitability

EPS (Most Recent Fiscal Year)$15.15
Net Income$4.27 billion
Net Margins28.17%
Return on Equity14.19%
Return on Assets6.86%

Miscellaneous

Employees23,044
Outstanding Shares303,950,000

How to Become a New Pot Stock Millionaire

Shire (NASDAQ:SHPG) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire pay dividends? What is the dividend yield for Shire?

Shire announced a semiannual dividend on Friday, February 16th. Stockholders of record on Friday, March 9th will be given a dividend of $0.8937 per share on Tuesday, April 24th. This represents a dividend yield of 1.33%. The ex-dividend date of this dividend is Thursday, March 8th. This is an increase from Shire's previous semiannual dividend of $0.15. View Shire's Dividend History.

How were Shire's earnings last quarter?

Shire (NASDAQ:SHPG) released its quarterly earnings data on Thursday, April, 26th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.58 by $0.21. Shire had a net margin of 28.17% and a return on equity of 14.19%. View Shire's Earnings History.

When is Shire's next earnings date?

Shire is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Shire.

What guidance has Shire issued on next quarter's earnings?

Shire issued an update on its FY18 earnings guidance on Wednesday, February, 14th. The company provided earnings per share guidance of $14.90-15.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.02. The company issued revenue guidance of 15.4-15.9 billion, compared to the consensus revenue estimate of $15.47 billion.

What price target have analysts set for SHPG?

16 equities research analysts have issued 1-year price objectives for Shire's shares. Their forecasts range from $150.00 to $245.00. On average, they expect Shire's share price to reach $204.6429 in the next twelve months. View Analyst Ratings for Shire.

What are Wall Street analysts saying about Shire stock?

Here are some recent quotes from research analysts about Shire stock:
  • 1. Cantor Fitzgerald analysts commented, "Though it has not been confirmed by Shire yet, headlines from Reuters are reporting that Takeda (Not Covered) has made a takeover offer to Shire worth ~46.50 pounds/share (~$198 per ADS), which we estimate translates to ~ $61B (see Exhibit 1 on page 3 for details). Based on our conversations with shareholders, this seems like a reasonable starting price for a negotiation, but we think people will want to see $200+ unless it’s all cash." (4/16/2018)
  • 2. According to Zacks Investment Research, "Sales of Shire’s Mydayis showed promise in the first six months of launch. Also, strong performance of Vyvanse, Cinryze and Elaprase continue to drive its top line. The label expansion of Firazyr in pediatrics and approval of Lyophilized Oncaspar in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio. Though the adult ADHD space is one of the largest and fastest growing segments of the market, it is highly genericized. Supply shortage for Cinryze and generic competition for Lialda had an unfavorable impact on the top line. Moreover, its shares have underperformed the industry in the past year. Estimates have remained stable ahead of the Q1 earnings results. The company has a positive record of earnings surprises in recent quarters." (4/9/2018)
  • 3. Royal Bank of Canada analysts commented, "We don’t have a clue on the contribution of PhotonBlade in the qtr. FY18 guidance will be critical. Consensus currently is ~$52M. A number below consensus will be parsed almost immediately as to implied PhotonBlade / non- PhotonBlade growth." (2/5/2018)

Who are some of Shire's key competitors?

Who are Shire's key executives?

Shire's management team includes the folowing people:
  • Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
  • Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
  • Gisele Dion, Chief Accounting Officer
  • Mr. Matthew Walker, Head of Technical Operations (Age 54)
  • Prof. Andreas Busch Ph.D., Head of R&D, Chief Scientific Officer & Exec. VP (Age 55)

Has Shire been receiving favorable news coverage?

News coverage about SHPG stock has trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Shire earned a daily sentiment score of 0.12 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.41 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Shire?

Shares of SHPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire's stock price today?

One share of SHPG stock can currently be purchased for approximately $163.62.

How big of a company is Shire?

Shire has a market capitalization of $49.40 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis. Shire employs 23,044 workers across the globe.

How can I contact Shire?

Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]


MarketBeat Community Rating for Shire (SHPG)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  898 (Vote Outperform)
Underperform Votes:  436 (Vote Underperform)
Total Votes:  1,334
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHPG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Shire (NASDAQ:SHPG) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
16 Wall Street analysts have issued ratings and price targets for Shire in the last 12 months. Their average twelve-month price target is $204.6429, suggesting that the stock has a possible upside of 25.07%. The high price target for SHPG is $245.00 and the low price target for SHPG is $150.00. There are currently 5 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.692.712.572.67
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $204.6429$204.00$212.1818$219.25
Price Target Upside: 25.07% upside53.02% upside34.90% upside49.87% upside

Shire (NASDAQ:SHPG) Consensus Price Target History

Price Target History for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2018B. RileyBoost Price TargetBuy$200.00LowView Rating Details
4/16/2018Cantor FitzgeraldSet Price TargetBuy$222.00MediumView Rating Details
3/28/2018Bank of AmericaReiterated RatingBuyHighView Rating Details
2/20/2018SunTrust BanksLower Price TargetBuy$190.00MediumView Rating Details
2/20/2018JPMorgan ChaseReiterated RatingOverweight -> NeutralMediumView Rating Details
2/16/2018Royal Bank of CanadaLower Price TargetOutperform$181.00LowView Rating Details
2/14/2018Sanford C. BernsteinUpgradeMarket Perform -> OutperformMediumView Rating Details
1/5/2018CowenSet Price TargetBuy$225.00LowView Rating Details
1/3/2018Piper JaffrayReiterated RatingHoldLowView Rating Details
12/20/2017Liberum CapitalReiterated RatingBuy -> HoldMediumView Rating Details
10/30/2017FBR & CoReiterated RatingBuy$201.00N/AView Rating Details
10/8/2017Stifel NicolausReiterated RatingBuy$245.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$196.00MediumView Rating Details
8/11/2017BarclaysDowngradeOverweight -> Equal WeightLowView Rating Details
8/9/2017Jefferies GroupReiterated RatingHold$216.00 -> $206.00LowView Rating Details
7/17/2017BTIG ResearchReiterated RatingBuy$242.00LowView Rating Details
4/17/2017Goldman SachsBoost Price TargetOverweight$202.00 -> $214.00LowView Rating Details
2/17/2017GuggenheimReiterated RatingNeutralN/AView Rating Details
12/6/2016UBSDowngradeBuy -> HoldN/AView Rating Details
12/2/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
11/14/2016Leerink SwannSet Price TargetBuy$198.00N/AView Rating Details
11/3/2016CitigroupReiterated RatingBuyN/AView Rating Details
11/2/2016Deutsche BankReiterated RatingBuyN/AView Rating Details
10/23/2016BNP ParibasReiterated RatingBuyN/AView Rating Details
10/8/2016Shore CapitalReiterated RatingBuyN/AView Rating Details
6/3/2016Morgan StanleyReiterated RatingOverweightN/AView Rating Details
5/23/2016Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Shire (NASDAQ:SHPG) Earnings History and Estimates Chart

Earnings by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Earnings Estimates

2018 EPS Consensus Estimate: $15.62
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185$3.54$4.01$3.81
Q2 20185$3.63$4.13$3.85
Q3 20185$3.71$4.08$3.84
Q4 20185$3.78$4.37$4.12

Shire (NASDAQ SHPG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2018$3.58$3.37ViewN/AView Earnings Details
2/14/2018n/a$3.86$3.98$4.1449 billionViewN/AView Earnings Details
10/27/20179/30/2017$3.64$3.81$3.6976 billionViewN/AView Earnings Details
8/3/20176/30/2017$3.53$3.73$3.7458 billionViewListenView Earnings Details
5/2/2017Q1 17$3.22$3.63$3.5723 billionViewListenView Earnings Details
2/16/2017Q416$3.24$3.37$3.7752 billion$3.8061 billionViewN/AView Earnings Details
11/1/2016Q316$3.21$3.17$3.57 billion$3.45 billionViewN/AView Earnings Details
8/2/2016Q216$3.03$3.38$2.2757 billion$2.43 millionViewN/AView Earnings Details
4/29/2016Q1$3.0540$3.19$1.71 billion$1.71 billionViewListenView Earnings Details
2/11/2016Q415$2.89$2.97$1.69 million$1.7160 billionViewListenView Earnings Details
10/23/2015Q315$2.87$3.24$1.63 billion$1.58 billionViewListenView Earnings Details
7/23/2015Q215$2.81$2.63$1.59 billion$1.56 billionViewListenView Earnings Details
4/30/2015Q115$2.56$2.84$1.47 billion$1.49 billionViewN/AView Earnings Details
2/12/2015Q115$2.68$2.63$1.5293 billion$1.5761 billionViewN/AView Earnings Details
10/24/2014Q314$2.47$2.93$1.46 billion$1.55 billionViewListenView Earnings Details
7/18/2014Q214$2.45$2.67$1.45 billion$1.50 billionViewN/AView Earnings Details
5/1/2014Q114$2.22$2.36$1.38 billion$1.35 billionViewN/AView Earnings Details
2/13/2014Q413$2.02$2.26$1.28 billion$1.33 billionViewN/AView Earnings Details
10/24/2013Q213$1.65$1.77$1.23 billion$1.24 billionViewN/AView Earnings Details
7/25/2013$1.60$1.79$1.2146 billion$1.2750 billionViewN/AView Earnings Details
5/2/2013Q113$1.56$1.63$1.21 billion$1.16 billionViewN/AView Earnings Details
2/14/2013Q412$1.58$1.58$1.20 billion$1.20 billionViewN/AView Earnings Details
10/25/2012$1.47$1.36ViewN/AView Earnings Details
8/1/2012$1.52$1.68ViewN/AView Earnings Details
4/26/2012$0.52$1.24ViewN/AView Earnings Details
2/9/2012$0.48$0.44ViewN/AView Earnings Details
10/28/2011$1.31$1.28ViewN/AView Earnings Details
7/28/2011$1.24$1.33ViewN/AView Earnings Details
4/28/2011$1.18$1.23ViewN/AView Earnings Details
2/10/2011$1.04$1.03ViewN/AView Earnings Details
10/29/2010Q3 2010$0.98$1.16ViewN/AView Earnings Details
8/4/2010Q2 2010$0.88$1.03ViewN/AView Earnings Details
4/29/2010Q1 2010$0.84$1.01ViewN/AView Earnings Details
2/19/2010Q4 2009$0.58$1.10ViewN/AView Earnings Details
10/30/2009Q3 2009$0.48$0.49ViewN/AView Earnings Details
8/5/2009Q2 2009$0.47$0.60ViewN/AView Earnings Details
4/30/2009Q1 2009$1.08$1.28ViewN/AView Earnings Details
2/19/2009Q4 2008$1.00$1.01ViewN/AView Earnings Details
10/29/2008Q3 2008$0.87$1.17ViewN/AView Earnings Details
7/31/2008Q2 2008$0.75$0.95ViewN/AView Earnings Details
4/25/2008Q1 2008$0.72$0.74ViewN/AView Earnings Details
2/21/2008Q4 2007$0.64$0.94ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Shire (NASDAQ:SHPG) Dividend Information

Shire pays an annual dividend of $1.05 per share, with a dividend yield of 0.64%. SHPG's next semiannual dividend payment will be made on Tuesday, April 24. Shire pays out 6.93% of its earnings out as a dividend.
Next Dividend:4/24/2018
Annual Dividend:$1.05
Dividend Yield:0.64%
Payout Ratio:6.93% (Trailing 12 Months of Earnings)
6.90% (Based on This Year's Estimates)
6.44% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/16/2018semiannual$0.89371.33%3/8/20183/9/20184/24/2018
8/11/2017semiannual$0.15270.21%9/7/20179/8/201710/20/2017
2/24/2017$0.77103/8/20173/10/20174/25/2017
8/5/2016$0.13909/7/20169/9/201610/7/2016
2/11/2016$0.66503/9/20163/11/20164/12/2016
7/23/2015$0.12639/2/20159/4/201510/2/2015
2/23/2015semiannual$0.57270.48%3/11/20153/13/20154/14/2015
8/4/2014semiannual$0.11490.09%9/3/20149/5/201410/3/2014
2/20/2014semiannual$0.50790.61%3/5/20143/7/20144/8/2014
7/29/2013semiannual$0.090.16%9/4/20139/6/201310/3/2013
2/19/2013semiannual$0.43800.92%3/6/20133/8/20134/9/2013
(Data available from 1/1/2013 forward)

Insider Trades

Shire (NASDAQ SHPG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 19.58%
Insider Trading History for Shire (NASDAQ:SHPG)
Insider Trading History for Shire (NASDAQ:SHPG)

Shire (NASDAQ SHPG) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Shire (NASDAQ SHPG) News Headlines

Source:
DateHeadline
Takeda sweetens offer for Shire to £47/shareTakeda sweetens offer for Shire to £47/share
seekingalpha.com - April 20 at 10:28 AM
Brainstorm Health: The Gene Testing Perk, Shire Takeover Drama, Marijuana-Based Epilepsy DrugBrainstorm Health: The Gene Testing Perk, Shire Takeover Drama, Marijuana-Based Epilepsy Drug
fortune.com - April 20 at 8:20 AM
Rare Disease Drug Maker Shires Stock Spikes Amid Bidding War Between Allergan and TakedaRare Disease Drug Maker Shire's Stock Spikes Amid Bidding War Between Allergan and Takeda
fortune.com - April 20 at 8:20 AM
Stocks to watch: Shire, Reckitt, Hammerson, Ericsson, EsureStocks to watch: Shire, Reckitt, Hammerson, Ericsson, Esure
www.ft.com - April 20 at 8:20 AM
Third Time Unlucky for Takeda and ShireThird Time Unlucky for Takeda and Shire
www.wsj.com - April 20 at 8:20 AM
Losing direction: Allergan investors are unhappy after a wild 4-hour takeover drama'Losing direction': Allergan investors are unhappy after a wild 4-hour takeover drama
www.businessinsider.com - April 20 at 8:20 AM
Shire Rebuff May Not Dim Takedas Appetite for a TakeoverShire Rebuff May Not Dim Takeda's Appetite for a Takeover
www.bloomberg.com - April 20 at 8:20 AM
[$$] Shire shares down 3.7% after Allergan rules out bid[$$] Shire shares down 3.7% after Allergan rules out bid
finance.yahoo.com - April 20 at 8:19 AM
Japans Takeda shares drop as investors fret over Shire pursuitJapan's Takeda shares drop as investors fret over Shire pursuit
finance.yahoo.com - April 20 at 8:19 AM
FTSE 100 rises, as pound falls on BOE rate-hike doubtsFTSE 100 rises, as pound falls on BOE rate-hike doubts
finance.yahoo.com - April 20 at 8:19 AM
Takeda slips after Shire rejects $63B offerTakeda slips after Shire rejects $63B offer
seekingalpha.com - April 20 at 5:15 AM
Shire says it rejected Takeda’s first three takeover offers, including $60B bidShire says it rejected Takeda’s first three takeover offers, including $60B bid
www.bizjournals.com - April 19 at 5:44 PM
Takeda Says Shire (SHPG) Rejected GBP 46.50 per Share OfferTakeda Says Shire (SHPG) Rejected GBP 46.50 per Share Offer
www.streetinsider.com - April 19 at 5:44 PM
CNBC: Allergan-Shire Deal Is DOACNBC: Allergan-Shire Deal Is DOA
finance.yahoo.com - April 19 at 5:44 PM
Is Shire plc’s (NASDAQ:SHPG) PE Ratio A Signal To Buy For Investors?Is Shire plc’s (NASDAQ:SHPG) PE Ratio A Signal To Buy For Investors?
finance.yahoo.com - April 19 at 5:44 PM
Shire (SHPG) Comments on Proposals from Takeda PharmaceuticalShire (SHPG) Comments on Proposals from Takeda Pharmaceutical
www.streetinsider.com - April 19 at 5:44 PM
B. Riley Increases Shire (SHPG) Price Target to $200.00B. Riley Increases Shire (SHPG) Price Target to $200.00
www.americanbankingnews.com - April 19 at 3:33 PM
Allergan will not bid for Shire: SourcesAllergan will not bid for Shire: Sources
www.cnbc.com - April 19 at 1:19 PM
Shire (SHPG) Given a $222.00 Price Target at Cantor FitzgeraldShire (SHPG) Given a $222.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - April 19 at 12:16 PM
AbbVie down 2% on investor concerns with potential interest in ShireAbbVie down 2% on investor concerns with potential interest in Shire
seekingalpha.com - April 19 at 12:07 PM
Stocks to watch: Weir, Shire, Publicis, Ultra Electronics, WPPStocks to watch: Weir, Shire, Publicis, Ultra Electronics, WPP
www.ft.com - April 19 at 8:12 AM
Takeda Offers About $60 Billion for Shire, Reuters SaysTakeda Offers About $60 Billion for Shire, Reuters Says
www.bloomberg.com - April 19 at 8:12 AM
[$$] Takeda makes £42.4bn bid for Shire[$$] Takeda makes £42.4bn bid for Shire
finance.yahoo.com - April 19 at 8:11 AM
Takeda makes $61 billion bid for drugmaker Shire - sourcesTakeda makes $61 billion bid for drugmaker Shire - sources
finance.yahoo.com - April 19 at 8:11 AM
Brokers Issue Forecasts for Shires Q1 2018 Earnings (SHPG)Brokers Issue Forecasts for Shire's Q1 2018 Earnings (SHPG)
www.americanbankingnews.com - April 19 at 5:58 AM
Shire (SHPG) to Release Earnings on ThursdayShire (SHPG) to Release Earnings on Thursday
www.americanbankingnews.com - April 19 at 2:52 AM
FY2019 Earnings Forecast for Shire (SHPG) Issued By SunTrust BanksFY2019 Earnings Forecast for Shire (SHPG) Issued By SunTrust Banks
www.americanbankingnews.com - April 18 at 8:52 AM
FDA OKs expanded use for Shires Vonvendi; shares up 2% premarketFDA OKs expanded use for Shire's Vonvendi; shares up 2% premarket
seekingalpha.com - April 17 at 10:12 AM
Shire plc : FDA APPROVES VONVENDI® FOR PERIOPERATIVE MANAGEMENT OF BLEEDING IN ADULT PATIENTS WITH VON WILLEBRAND DISEASEShire plc : FDA APPROVES VONVENDI® FOR PERIOPERATIVE MANAGEMENT OF BLEEDING IN ADULT PATIENTS WITH VON WILLEBRAND DISEASE
feeds.benzinga.com - April 17 at 9:51 AM
On World Hemophilia Day 2018, Shire Unites Communities in Asia Pacific and Advocates for Principles of CareOn World Hemophilia Day 2018, Shire Unites Communities in Asia Pacific and Advocates for 'Principles of Care'
finance.yahoo.com - April 17 at 8:24 AM
Shire (SHPG) Downgraded by BidaskClub to "Strong Sell"Shire (SHPG) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - April 16 at 11:29 PM
Cantor Fitzgerald Analysts Give Shire (SHPG) a $222.00 Price TargetCantor Fitzgerald Analysts Give Shire (SHPG) a $222.00 Price Target
www.americanbankingnews.com - April 16 at 8:18 AM
BRIEF-Shire Sells Oncology Business To Servier For $2.4 BillionBRIEF-Shire Sells Oncology Business To Servier For $2.4 Billion
www.reuters.com - April 16 at 8:12 AM
Sorrell Out, Shire Slims, Data Monopolies: CEO Daily for April 16, 2018Sorrell Out, Shire Slims, Data Monopolies: CEO Daily for April 16, 2018
fortune.com - April 16 at 8:12 AM
Shire to Sell Oncology Unit for $2.4 Billion as Takeda Mulls TakeoverShire to Sell Oncology Unit for $2.4 Billion as Takeda Mulls Takeover
www.wsj.com - April 16 at 8:12 AM
Shires $2.4 Billion Cancer-Unit Sale Sweetens Takeda AppealShire's $2.4 Billion Cancer-Unit Sale Sweetens Takeda Appeal
finance.yahoo.com - April 16 at 8:12 AM
Shire to Sell Oncology Business to Servier for $2.4 BillionShire to Sell Oncology Business to Servier for $2.4 Billion
finance.yahoo.com - April 16 at 8:12 AM
[$$] Shire to Sell Oncology Unit for $2.40 Billion[$$] Shire to Sell Oncology Unit for $2.40 Billion
finance.yahoo.com - April 16 at 8:12 AM
Shire to sell oncology unit to Servier for $2.4 billionShire to sell oncology unit to Servier for $2.4 billion
finance.yahoo.com - April 16 at 8:12 AM
[$$] Shire sells oncology unit to France’s Servier for $2.4bn[$$] Shire sells oncology unit to France’s Servier for $2.4bn
finance.yahoo.com - April 16 at 8:12 AM
FTSE 100 pulled lower by slump for WPPFTSE 100 pulled lower by slump for WPP
finance.yahoo.com - April 16 at 8:12 AM
[$$] Shire to Sell Oncology Unit as Takeda Mulls Takeover[$$] Shire to Sell Oncology Unit as Takeda Mulls Takeover
finance.yahoo.com - April 16 at 8:12 AM
Shire sells cancer drugs to Servier for $2.4 billion as Takeda circlesShire sells cancer drugs to Servier for $2.4 billion as Takeda circles
finance.yahoo.com - April 16 at 8:12 AM
Shire sells oncology unit for £1.7bn as Takeda boss prepares potential bidShire sells oncology unit for £1.7bn as Takeda boss prepares potential bid
uk.finance.yahoo.com - April 16 at 8:12 AM
Shire to sell oncology unit for $2.4BShire to sell oncology unit for $2.4B
seekingalpha.com - April 16 at 4:49 AM
Shire plc : Shire Announces Sale of Oncology Business to Servier for $2.4 BillionShire plc : Shire Announces Sale of Oncology Business to Servier for $2.4 Billion
feeds.benzinga.com - April 16 at 3:58 AM
Shire (SHPG) Given a $159.00 Price Target at Piper JaffrayShire (SHPG) Given a $159.00 Price Target at Piper Jaffray
www.americanbankingnews.com - April 15 at 11:42 PM
Report: Exploring Fundamental Drivers Behind Shire plc, Bank Of Montreal, Companhia Paranaense de Energia ...Report: Exploring Fundamental Drivers Behind Shire plc, Bank Of Montreal, Companhia Paranaense de Energia ...
globenewswire.com - April 13 at 8:15 AM
Shire (SHPG) Upgraded to Hold at Zacks Investment ResearchShire (SHPG) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 12 at 7:25 PM
Takeda sounds out banks for loans as it moves towards Shire bid: sourcesTakeda sounds out banks for loans as it moves towards Shire bid: sources
www.reuters.com - April 12 at 8:26 AM

SEC Filings

Shire (NASDAQ:SHPG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Shire (NASDAQ:SHPG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Shire (NASDAQ SHPG) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.